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Abstract. Malaria remains a challenging diagnosis with variable clinical presentation and a wide spectrum of disease
severity. Using a structured case report form, we prospectively assessed 1,933 children at Mulago Hospital in Kampala,
Uganda with acute Plasmodium falciparum malaria. Children with uncomplicated malaria significantly differed from
those with severe disease for 17 features. Among 855 children with severe disease, the case-fatality rate increased as
the number of severity features increased. Logistic regression identified five factors independently associated with
death: cerebral malaria, hypoxia, severe thrombocytopenia, leukocytosis, and lactic acidosis. Cluster analysis identified
two groups: one combining anemia, splenomegaly, and leukocytosis; and a second group centered on death, severe
thrombocytopenia, and lactic acidosis, which included cerebral malaria, hypoxia, hypoglycemia, and hyper-parasitemia.
Our report updates previous clinical descriptions of severe malaria, quantifies significant clinical and laboratory inter-
relationships, and will assist clinicians treating malaria and those planning or assessing future research (NCT00707200)
(www.clinicaltrials.gov).
INTRODUCTION
Children with malaria have a wide variety of signs and symp-
toms. The World Health Organization recognizes numerous
hallmark features of severe malaria (Table 1).1 Acute malaria
syndromes carry diagnostic value and prognostic importance,
but do not occur with equal prevalence among different age
groups and across different regions. The severity of clinical
infection in malaria depends on complex interactions of host,
parasite, and environmental factors.1
Numerous previous studies have analyzed clinical features
in malaria. Early work by Marsh and others established that
three overlapping syndromes were found in severe disease:
cerebral malaria (CM), respiratory distress (RD), and severe
malaria anemia (SMA).2,3 Subsequent reports further char-
acterized the clinical findings of malaria and established fun-
damental patterns of the illness.4–14 These patterns include
the importance of impaired consciousness as a risk-factor for
fatal outcome, the value of blood transfusion in the treatment
of severe anemia, hypoglycemia during acute illness, and
the observation of RD as a manifestation of lactic acidosis
(LA). These studies were published more than 15 years ago
and most were based on < 500 patients.
During 2000–2010, additional reports refined the case defini-
tions of severe malaria. Two studies of children with severe
malaria in Gabon and a third study from Mali reported that
mortality was associated with CM, hypoglycemia, RD and
LA.15–17 These reports were unable to assess the contribu-
tion of increased blood lactate levels, thrombocytopenia, and
leukocytosis to outcomes. Idro and others18 provided a detailed
description of 100 children with CM treated in Uganda and
identified RD, circulatory failure, hyporeflexia, and hyper-
parasitemia as additive risk factors for fatal outcomes. In a
subsequent report of more than 9,000 children in Kenya with
malaria, they confirmed that acidosis, hypoglycemia, and cir-
culatory collapse were associated with neurologic signs.19
Smaller studies from Ghana20 and Gabon21 and a multicenter
sub-Saharan study22 further defined complications of severe
disease. In a review of 25 previously published studies, Roca-
Feltrer and others reported that the age distribution for
SMA was consistently younger than that for CM.23 Recently,
Vekemans and others24 provided a thorough review of the
published literature through 2010 and suggested a standard-
ized case definition for severe malaria for use in a multi-
center phase III vaccine trial. Their report provides the most
up-to-date approach to classifying severe malaria on the basis
of previously available data.
In this report, we present results of a prospective obser-
vational study of clinical and laboratory features among
1,933 children with acute Plasmodium falciparum malaria at
Mulago Hospital during 2007–2009. We used newer clinical
assays, including blood lactate levels, oximetry, and complete
blood counts. We present data on the prevalence of major
malaria syndromes; the impact of specific syndromes on
case-fatality rates; and, for the first time, a cluster analysis of
the extent of association between different clinical features
present in a large cohort of children with severe malaria. Our
findings update the clinical description of severe malaria in
children, respond to requests for improved case definitions
for severe malaria,25 and may suggest new research targets
and novel treatments for specific sub-groups of patients.
METHODS
Study population. Children 6 months to 12 years of age
with either uncomplicated or severe malaria were enrolled in
a prospective observational study conducted at the Acute
Care Unit of Mulago Hospital in Kampala, Uganda.26 Mulago
Hospital is a 1,500 bed national referral center and teaching
hospital of Makerere University College of Health Sciences
where a previous study documented a 4.2% case-fatality rate
among 23,342 children with malaria.27 Children were enrolled
during October 2007–October 2009. The diagnosis of malaria
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was suspected on the basis of clinical symptoms and a posi-
tive thick blood smear examined by an experienced labo-
ratory technician, and subsequently confirmed by two expert
reviewers from a reference parasitology laboratory who
examined in a blinded fashion thick and thin blood smears
from each person. Uncomplicated malaria was defined as
the absence of any impairment of consciousness or hypoxia,
with peripheral blood lactate levels < 5 mM and hemoglobin
(Hb) levels > 7 g/dL without transfusion. Severe malaria was
defined as impaired consciousness, arterial oxygen satura-
tion < 90%, blood lactate levels > 5 mM, or an Hg level
< 5 g/dL (or < 6 g/dL if tested after transfusion). Children
who did not meet the above criteria for either uncomplicated
or severe malaria were not enrolled in the study so that analysis
would contrast the spectrum of malaria severity.
All enrolled persons were tested for infection with human
immunodeficiency virus (HIV);26 forty-five were positive and
were excluded from the analysis so that the clinical description
would represent the effects of malaria alone. For each child,
a parent or guardian provided written informed consent for
participation in accordance with guidelines of the research
ethics committees of the Makerere University College of
Health Sciences and the University of Toronto.
Data collection. Two physicians (CM and AD) experienced
in malaria care of children enrolled, evaluated, and recorded
all information. All available clinical resources were used to
assess the presence of coexisting bacterial infection or other
medical conditions. Commercially available devices were used
to measure complete blood count (ACT*8; Beckman Coulter,
Brea, CA), blood lactate (LactatePro LT-1710; Arkray, Kyoto,
Japan), oxygen saturation (Nonin, Plymouth, MN), and glucose
(Ascensia Contour; Bayer HealthCare LLC, Mishawaka, IN).
The presence of Hb S was tested by using a commercial solu-
bility assay (SickleDex; Streck, Omaha, NE). ABO and rhesus
blood grouping was determined by using commercial reagents
according to manufacturer’s directions. Quantitative parasite
counts were determined by two independent observers counting
the number of parasitized erythrocytes indexed to 200 leuko-
cytes and then corrected for the actual leukocyte count.26 Struc-
tured clinical data for each person were collected in a uniform
fashion by using a case report form (CRF) (www.cd36malaria
.org). Data from the hard-copy CRF was transferred to a digital
CRF (prepared with FileMaker Pro 9.0 version 1; FileMake,
Santa Clara, CA) for subsequent analysis. Data accuracy and
quality control were performed as reported.26
Severe malaria categories. On the basis of their clinical and
laboratory results, children with severe malaria were assigned
to one or more of the following categories: severe malaria
anemia Hb level < 5 g/dL (or < 6 g/dL after transfusion); lactic
acidosis: blood lactate level > 5 mM; severe thrombocytopenia:
platelet count < 50,000/mL; leukocytosis: total leukocyte
count > 10,000 cells/mL; hyper-parasitemia: > 5% of eryth-
rocytes parasitized; hypoxia: peripheral oxygen saturation
< 90% while breathing ambient air; and hypoglycemia:
blood glucose level < 2.2 mM.
We categorized persons as having CM if they met both
of the following two criteria. First, the patient had coma or a
Blantyre Coma Scale £ 2 provided that the coma was present
for > 6 hours and was not attributable to hypoglycemia,
meningitis, non-malaria-related pre-existing neurologic abnor-
malities, or drugs such as anticonvulsants or other agents
with sedative/hypnotic effects. Second, the patient met either
or both of the following two severity criteria: the patient had
> 3 of the following 10 World Health Organization severity
criteria: 1) > 2 seizures in 24 hours, RD, jaundice, hemo-
globinuria, spontaneous bleeding, hypoglycemia (glucose
level < 2.2 mM), LA (lactate level > 5 mM), normocytic
severe anemia, hyper-parasitemia >5%, or new acute renal
failure; or 2) the patient had a cumulative score of ³ 3 points
on a previously reported scale of neurologic involvement.26
Statistical analysis. Continuous data are reported as a median
with inter-quartile ranges (IQRs), and were compared by using
the Wilcoxon test. Categorical data were compared using the
chi-square test. All comparisons were two-tailed and a P value
< 0.05 was considered significant. Associations between pairs
of categories of severe malaria are presented as odds ratios.
Logistic regression was used to determine the odds ratios
for the outcome of death using input terms found to have
significant association with death in 2 + 2 analysis or known
to have a published biologic relationship to adverse outcomes
in malaria: presence of CM, hypoxia, severe thrombocytopenia,
leukocytosis, LA, hyper-parasitemia, SMA, Hb S, blood
group A, age < 1.5 years, and female sex. Of the 855 children
with severe malaria, 798 had recorded values for the above 11
input terms and formed the basis for the regression. The enroll-
ment of approximately 1,000 uncomplicated and 1,000 severe
malaria patients was designed to detect a difference of ³ 6%
with 80% power between uncomplicated and severe malaria
patients for clinical features with a prevalence of 25–50%.
Ethics. The study was approved by the Makerere University
School of Medicine Research Ethics Committee, the Toronto
AcademicHealth ScienceNetworkResearchEthicsBoard, and
the Uganda National Council for Science and Technology. The
studywas registered at www.clinicaltrials.gov as NCT00707200.
RESULTS
A total of 2,092 children six months to 12 years of age
with either uncomplicated malaria or severe malaria were
Table 1
World Health Organization features of malaria
Features
Clinical
Impaired consciousness or unrousable coma
Prostration (generalized weakness; unable to walk or sit up
without assistance)
Failure to feed
Multiple convulsions (> 2 episodes in 24 hours)
Deep breathing, respiratory distress (acidotic breathing)
Circulatory collapse or shock (systolic blood pressure < 50 mm Hg
in children)
Clinical jaundice plus evidence of other vital organ dysfunction
Hemoglobinuria
Abnormal spontaneous breathing
Pulmonary edema (radiologic)
Laboratory findings
Hypoglycemia (blood glucose level < 2.2 mM)
Metabolic acidosis (plasma bicarbonate level < 15 mM)
Severe normocytic anemia (hemoglobin level < 5 g/dL)
Hemoglobinuria
Hyper-parasitemia (> 2% or 100,00 parasites/mL in
low-intensity transmission areas or > 5% or
250,00 parasites/mL in areas of high, stable malaria
transmission intensity
Hyper-lactatemia (lactate level > 5 mM)
Renal impairment (serum creatinine level > 265 mmol/L)
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enrolled. After study completion, 159 were excluded, leav-
ing 1,933 available for analysis. Reasons for exclusion
(specified before the study) were: HIV positivity (n = 45),
not infected with P. falciparum (n = 35), and not meeting
pre-study definitions for uncomplicated or severe disease
(n = 79). Illness was attributed exclusively to malaria in
nearly all children. For example, among those categorized as
having CM (n = 174), one-third (n = 56) had a lumbar punc-
ture performed and none of these children showed evidence
of meningitis. Only 38 children received antibiotics for
unconfirmed but suspected coexisting bacterial infections.
Levels of parasitized erythrocytes were > 2,500/mL in 94% of
children28 and > 5,000/mL in 91%.24
All patients were treated by pediatricians expert in malaria
care. Intravenous quinine was used in 99% of children with
severe malaria. Intravenous hydration, oxygen, and anti-seizure
medications were used as needed. Transfusion therapy was
readily available. Among 653 patients for whom blood was
requested for transfusion, only one failed to receive a trans-
fusion, three received fewer than the prescribed units, and
29 experienced some delay before the start of transfusion
because of blood availability.
Clinical and laboratory features of 1,933 children are
shown in Table 2. Of these children, 1,078 were classified
as having uncomplicated malaria and 855 children were
classified as having severe malaria on the basis of enroll-
ment features of neurologic involvement, SMA, LA, or
hypoxia. In addition to these enrollment features, children
with severe malaria differed from those with uncomplicated
malaria for 17 other clinical or laboratory findings. The age
distribution of children is shown in Figure 1A. Severe
malaria was more common among children < 1.5 years of age.
Clinical and laboratory features among the 855 chil-
dren with severe malaria are shown in Table 3. The prev-
alence of findings for each of eight major clinical factors
is shown.
Cerebral malaria (n = 174). Hypoglycemia was excluded
as a cause of impaired consciousness in nearly all (93%)
children categorized as having CM. Patients with CM were
distinct from those with SMA; only 36 (4%) of 855 patients
had both syndromes. As reported,23 children with CM
were significantly older (median age = 2.5 years, IQR =
1.5–3.9 years) than those without CM (median age = 1.7 years,
IQR = 1.0–2.9 years) (P < 0.0001) (Figure 1B). Among
855 patients with any form of SM, those with CM had a
higher median Hb level (6.9 g/dL, IQR = 5.2–8.2 g/dL versus
4.2 g/dL, IQR = 3.4–4.9 g/dl; P < 0.0001) and a lower
median platelet count (73,000/mL, IQR = 43,000–129,500/mL
versus 110,000/mL, IQR = 66,000–170,000/mL; P < 0.0001)
than children without CM.
Respiratory distress (n = 518) and lactic acidosis (n = 481).
The presence of labored or deep breathing, nasal flaring,
Table 2
Clinical and laboratory features among 1,933 children with uncomplicated or severe Plasmodium falciparum malaria, Kampala, Uganda*
Characteristic
Uncomplicated malaria, n = 1,078 Severe malaria, n = 855
PValue No. Value No.
History and physical examination
Age, years (range) 2.9 (1.6–5.1) 1,078 1.8 (1.1–3.1) 855 < 0.0001
Body mass index (range) 15.4 (14–17) 797 14.8 (13.6–16.5) 655 < 0.0001
Sex (F:M) 521:557 1,078 402:453 855 0.60
Days ill before hospitalization (range) 3 (2–4) 1,078 3 (3–5) 855 < 0.0001
Temperature, °C (range) 38.2 (37.3–39) 660 37.8 (37.1–38.6) 492 < 0.0001
Patients with palpable spleen 157 (23%) 676 310 (62%) 504 < 0.0001
Patients with respiratory distress 74 (7%) 1,078 518 (61%) 855 < 0.0001
Jaundice 19 (4.1%) 460 88 (26.5%) 332 < 0.0001
Coma 0 (0%) 1,078 200 (23%) 855 NA
Recurrent seizures 0 (0%) 1,078 196 (23%) 855 NA
Blantyre coma score (range) ND ND 4 (4–5) 844 NA
Laboratory values upon presentation, median (IQR)
Hemoglobin (g/dL) 9.3 (8.2–10.4) 1,078 4.5 (3.6–6.3) 855 NA
MCV (fL) 84 (78–89) 1,077 84 (78–90) 855 0.61
Platelet count ( +109/L) 136 (81–217) 1,078 103 (60–170) 854 < 0.0001
Leukocyte count ( +109/L) 7.8 (5.9–10.3) 1,072 11.1 (7.7–16.7)] 853 < 0.0001
Absolute monocyte count ( +109/L) 0.5 (0.3–0.8) 1,065 0.8 (0.5–1.4) 847 < 0.0001
Parasitized erythrocytes/mL +1,000 83 (29–190) 1,063 91 (22–263) 831 0.13
% erythrocytes parasitized 2.2 (0.8–5.0) 1,062 4.6 (1.2–12.9) 831 < 0.0001
Hemoglobin S (%) 57 (6) 1,045 43 (5) 826 0.89
Glucose (mM) 5 (4.2–6) 65 5 (4.2–6.2) 248 0.65
Lactate (mM) 2.2 (1.6–3.0) 1,052 5.6 (3.1–8.3) 851 NA
Oximetry saturation (%) 99 (97–100) 1,052 97 (94–99) 849 NA
No. patients (%) with specific malaria syndromes
Cerebral malaria 0 (0) 1,078 174 (20) 855 NA
Lactic acidosis (> 5 mM) 0 (0) 1,052 482 (56) 851 NA
Severe malaria anemia (hemoglobin < 5 g/dL) 0 (0) 1,078 558 (65) 855 NA
Platelets < 50,000/mL 104 (10) 1,078 166 (19) 854 < 0.0001
Leukocytosis (leukocytes > 10,000/mL) 286 (27) 1,072 490 (57) 855 < 0.0001
Hyper-parasitemia (> 5% infected erythrocytes) 264 (25) 1,063 402 (48) 831 < 0.0001
Blood group A or AB 302 (28) 1,078 317 (37) 855 < 0.0001
Hypoxia (SaO2 < 90%) 0 (0) 1,052 43 (5) 849 NA
Hypoglycemia (< 2.2 mM) 0 (0) 65 22 (8.9) 248 < 0.0001
Death 0 (0) 1,078 48 (4.5) 855 < 0.0001
*Patients were categorized as having uncomplicated or severe malaria on the basis of neurologic findings, hemoglobin levels, blood lactate levels and oxygen saturation (see Methods). NA = not
applicable, feature defined enrollment category; ND = not determined; MCV, mean corpuscular volume; IQR, interquartile range; SaO2, arterial oxygen saturation.
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intercostal or subcostal retractions, or tachypnea (rate > 40 breaths/
minute) was directly related to disease severity but was not
caused by hypoxia. Respiratory distress was observed in 61%
of children with SM, but only 7% of those with uncomplicated
malaria (Table 2). Hypoxia, defined as an arterial oxygen
saturation < 90%, was observed in only 42 (8%) of 513 patients
with RD.
Rather than hypoxia, RD was highly associated with
LA (c2 = 113, P < 0.0001). Specifically, among 516 chil-
dren with RD, the median lactate level was 6.85 mM
(IQR = 4.5–10.4 mM); 71% had lactate levels > 5 mM and
94% had levels > 2 mM. These results are consistent with
those of previous investigators, who suggested that RD
represents a respiratory compensation to LA, rather than
respiratory drive from hypoxia or lung disease.8,11 Over-
all, among 1,903 children tested for blood lactate levels,
481 (25%) had levels > 5 mM. Lactic acidosis was found in
272 (49%) of 556 patients with SMA and in an additional
209 children (70%) with severe malaria without SMA.
Severe malaria anemia (n = 558). Severe malaria anemia
was observed in 65% of children with severe malaria. As noted
by others,23 patients with SMA were younger (Figure 1B).
Children with SMA had a slightly higher prevalence of
splenomegaly (68% versus 51%; P < 0.0001) than those with-
out SMA. Children with SMA also had higher absolute
monocyte counts (median = 1,020/mL, IQR = 600–1,580/mL)
than those without SMA (median = 547/mL, IQR = 319–886/mL)
(P < 0.0001).
Severe thrombocytopenia (n = 166). Thrombocytopenia at
admission was a strong indicator of disease severity (median
platelet count = 103,000/mL in patients with severe malaria
versus 136,000/mL in patients with uncomplicated disease)
(P < 0.0001). The proportion of children with a platelet
count < 50,000/mL was nearly twice as high (19%) among
those with severe syndromes than among those with uncom-
plicated malaria (10%) (c2 = 38, P < 0.0001). The number of
patients with CM trebled with platelet counts < 100,000/mL,
suggesting that 100,000/mL may be a more informative
threshold definition for severe thrombocytopenia in malaria
(Figure 2).
Hyper-parasitemia (n = 402). The concentration of para-
sitized erythrocytes varied widely, and the median concen-
tration was not statistically different between children with
uncomplicated disease and those with severe disease. How-
ever, as shown in Table 2, the proportion of children with
> 5% parasitized erythrocytes was significantly higher among
those with severe malaria (48%) than among those with
uncomplicated malaria (25%) (P < 0.0001). Nevertheless,
the presence of hyper-parasitemia had a positive predictive
value of only 60% for severe malaria, and the absence of
hyper-parasitemia had a negative predictive value of only
65% for severe malaria. Because the definition of hyper-
parasitemia depends on the ratio of infected erythrocytes
to total erythrocytes, the presence of anemia increases the
likelihood of being classified as hyper-parasitemic for any
given absolute concentration of parasitized erythrocytes
per microliter of whole blood.
Leukocytosis (n = 490). The median leukocyte count
was significantly higher in children with severe malaria
(11,100/mL) than in those with uncomplicated malaria
(7,800/mL) (P < 0.0001) (Table 2). Consistent with a host
inflammatory response to severe disease, a leukocyte count
> 10,000/mL was found in 66% of those with SMA, 67% of
those with hypoxia, and 77% of those with hypoglycemia
(Table 3).
Case-fatality rate. The CFR was significantly different
among patients with different severe malaria clinical fea-
tures (Table 3). The most striking difference was the low
CFR (2.8%) among patients with SMA than in those with
CM (19%) or severe thrombocytopenia (14.5%). There were
48 deaths attributed to malaria. Major clinical features
were found in the following percentages in fatal cases: LA
in 79%, CM in 69%, hyper-parasitemia in 62%, severe
thrombocytopenia in 50%, SMA in 31%, hypoglycemia in
33%, and hypoxia in 23%.
The relationship between CFR and the number of features
present in the same patient are shown in Figure 3. The CFRs
progressively increased with an increasing number of the
following hallmark features of malaria: CM, LA, SMA,
severe thrombocytopenia, and hyper-parasitemia. Logistic
regression was used to determine the odds ratios of a fatal
outcome according to the following 11 input variables: sex,
age < 1.5 years, CM, LA, SMA, severe thrombocytopenia,
Figure 1. Age distribution of children les than five years of age
with severe malaria, Kampala, Uganda. A, Age distribution among
children with uncomplicated versus severe malaria. B, Age distribu-
tion among children with cerebral malaria or severe anemia.
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leukocytosis, hyper-parasitemia, hypoxia, blood group A, and
presence of Hb S. Five factors had significant associations
with fatal outcome in the final model: CM, hypoxia, severe
thrombocytopenia, leukocytosis, and LA. Test results for
interactions among these five factors were found to be not
significant. The results are shown in Table 4.
Inter-relationships of malaria syndromes. Inter-relationships
between major clinical features of severe malaria are shown
in Table 5 and Figure 4. Clinical findings were assembled
into clusters on the basis of statistically significant positive
odds ratios. Two clusters of associations emerged. In the
first cluster, SMA, splenomegaly, and leukocytosis demon-
strated mutually significant positive associations of similar
magnitude. In the second cluster, seven features demon-
strated significant positive inter-relationships. Strong associa-
tions centered on the triad of death, severe thrombocytopenia,
and LA. Cerebral malaria was associated with death and
severe thrombocytopenia; hypoxia and hypoglycemia were
associated with death and LA; and hyper-parasitemia was
associated with LA and severe thrombocytopenia.
DISCUSSION
Using a standardized assessment, we have analyzed the
clinical features at hospitalization of 1,933 children with acute
malaria at Mulago Hospital in Kampala, Uganda. We con-
firmed results of previous reports that SMA affects younger
children and CM affects older children with malaria; that
LA is found both in association with SMA and independent
of SMA; and that RD was unrelated to hypoxia. Our data
update existing information on risk factors associated with
fatal outcomes in severe malaria.
The three largest recent studies on presenting features in
malaria are those of Dzeing-Ella and others,15 Issifou and
others,16 and Ranque and others,17 each of which enrolled
children more than a decade ago. Our study agrees with
the findings of those reports but includes a larger number
of children with severe malaria. In addition, we recorded
oxygen saturations, measured blood lactate levels for
> 10 times as many children, and were able to analyze the
independent contributions of thrombocytopenia and leuko-
cytosis to outcomes. Regarding fatal outcomes, we confirm
previous findings by many investigators that CM is the
principal cause of malaria death; that SMA has a low risk of
death if transfusions are available; that CFRs increase
in proportion to increasing numbers of co-existing severe
malaria features; and that LA and hypoglycemia are asso-
ciated with fatal outcomes. The CFR for children with
CM (19%) was similar to that reported by Marsh and
Table 4
Logistic regression for fatal outcome based on 798 children with
severe malaria, Kampala, Uganda*
Characteristic
Odds
ratio
95% Confidence
interval P
Cerebral malaria (CM) 10.9 4.8–25.0 < 0.0001
Hypoxia 6.9 2.5–19.1 0.0002
Severe thrombocytopenia 3.8 1.7–8.2 0.0008
Leukocytosis 3.0 1.3–6.9 0.0129
Lactic acidosis (LA) 2.4 1.0–5.5 0.0454
Blood group A 1.8 0.9–3.9 0.1077
Female sex 1.2 0.6–2.5 0.5930
Age < 1.5 years 1.1 0.5–2.5 0.8158
Hemoglobin S 1.0 0.2–6.1 0.9691
Hyper-parasitemia 0.9 0.4–1.8 0.6980
Severe malaria anemia (SMA) 0.7 0.3–1.5 0.3466
Characteristic
Odds
ratio
95% Confidence
interval P
Cerebral malaria (CM) 13.1 6.2–27.7 < 0.0001
Hypoxia 6.9 2.6–18.8 0.0001
Severe thrombocytopenia 3.6 1.7–7.5 0.0008
Leukocytosis 2.4 1.1–5.3 0.0303
Lactic acidosis (LA) 2.4 1.1–5.4 0.0351
*For the upper panel, Y = 2.4 + CM + 1.9 + Hypoxia + 1.3 + Thrombocytopenia + 1.1 +
Leukocytosis + 0.9 + LA – 5.86. For the lower panel, Y = 2.6 + CM + 1.9 + Hypoxia +
1.3 + Thrombocytopenia + 0.9 + Leukocytosis + 0.9 + LA – 5.70. Upper panel shows
the odds ratios and 95% confidence intervals for 11 input features of severe malaria.
(Model c2 = 96.7, degrees of freedom = 11, P < 0.0001). Lower panel shows the results
for the five statistically significant features. (Model c2 = 92.9, degrees of freedom – 5,
P < 0.0001). CM, hypoxia, severe thrombocytopenia, leukocytosis, LA, hyper-parasitemia,
and SMA were entered as dichotomous values as defined in the Methods.
Figure 2. Cerebral malaria according to platelet count at presen-
tation, Kampala. Uganda.
Figure 3. Increase in case-fatality rate (CFR) with increasing
number of severe malaria features, Kampala, Uganda. CFRs are
shown for 855 children with one or more combinations of the follow-
ing features: cerebral malaria, lactic acidosis, severe anemia, severe
thrombocytopenia, or hyper-parasitemia. The x-axis separates chil-
dren into five groups based on an increasing number of co-existing
severe malaria features present in combination. The groups show
an increasing median CFR. The size of each bubble indicates the
number of persons ranging from n = 558 for the single feature of
severe anemia (lower left) to n = 4 for all five features simultaneously
present (upper right).
752 CSERTI-GAZDEWICH AND OTHERS
others in 1995,2 suggesting little therapeutic advance for
this deadly syndrome. We extend existing reports by iden-
tifying with logistic regression five factors associated with
fatal outcomes: CM, hypoxia, severe thrombocytopenia,
leukocytosis, and LA.
The presence of severe thrombocytopenia was a clinically
important finding in our study with prognostic significance.
Children with severe malaria had lower median platelet
counts than those with uncomplicated malaria (Table 2). In
logistic regression analysis, death was 3.6 times more likely
in the presence of severe thrombocytopenia. Recent interest
has focused on the finding by McMorran and others29 that
growth of P. falciparum in vitro was inhibited by co-culture
with platelets. However, their non-flow, co-culture system
was unable to assess the role of platelets in the cytoadhesion
of parasitized erythrocytes to endothelium. Our clinical data
support the view that thrombocytopenia is associated with
poor outcomes30 and are consistent with the hypothesis
that platelets actively participate in the pathophysiology of
cytoadhesion in malaria.26,31–36
As shown in Figure 4, we determined inter-relationships
among the major clinical features of SM. We observed
two clusters of relationships, one cluster in children with
SMA, and a second cluster centered on death, severe
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Figure 4. Inter-relationships of clinical and laboratory findings
in 855 children with severe malaria, Kampala, Uganda. The odds
ratios for association between pairs of clinical and laboratory find-
ings were determined for 855 children with severe malaria. Those
features with a statistically significant positive odds ratio of associ-
ation are shown. The reciprocal of the loge of the odds ratio defines
the relative distance between spheres, and the number of persons
with each feature defines the volume of each sphere. Two clusters
of associations were observed. A, Cluster centered on severe malaria
anemia (SMA). B, Cluster of seven features. CM = cerebral malaria;
LA = lactic acidosis. Thrombocytopenia = platelet count < 50,000/mL.
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thrombocytopenia, and LA. These inter-relationships are
consistent with the three original major syndromes described
by Marsh and others2 (CM, SMA, and RD) and with three
potential pathophysiologic pathways shown in Figure 5.
One pathway emphasizes anemia that accompanies some
patients with malaria. With blood transfusion, children
with SMA can be rescued and fatal outcomes averted.6
Without transfusion, severe anemia will result in insufficient
tissue oxygenation, LA, and RD. A second pathway empha-
sizes cytoadhesion and microvascular ischemia in the cen-
tral nervous system resulting in CM. In our dataset, severe
thrombocytopeniawas strongly associatedwithCM(Figure 2,
Figure 4, and Table 5), suggesting an important role for
platelet-mediated cytoadhesion in the cerebral vasculature
as suggested by several authors.31,32,34,37 A third pathway,
also directly associated with severe thrombocytopenia, is
systemic LA in the absence of CM or SMA (Figure 4 and
Table 5). Lactic acidosis with accompanying RD presum-
ably results from microvascular tissue ischemia outside the
central nervous system, and in severe cases is associated
with hypoglycemia and death. Further research to identify
which host or parasite factors favor cytoadhesion in the
cerebral vasculature versus the non-cerebral circulation is
expected to be of value in guiding new therapies.
Our study had the following limitations. Results are based
only on children who were hospitalized. Thus, our data do
not reflect general prevalence rates for children at risk for
malaria. Serial laboratory data and clinical follow-up data
were not collected. We did not collect data for renal func-
tion, levels of malaria pigment found in leukocytes, cytokines,
retinal examination in all patients with suspected CM or the
relative distribution of parasite maturity in peripheral blood.
However, none of these features was considered essential in
the clinical assessment of malaria by a recent panel of experts.24
In summary, we update presenting features of pediatric
malaria on the basis of a prospective, uniform, clinical and
laboratory assessment of approximately 2,000 children treated
at an urban medical center in Uganda. Our data emphasize
the clinical distinction between uncomplicated and severe
malaria, report the prevalence of cardinal features that char-
acterize syndromes of severe malaria, quantify clustered
inter-relationships among malaria syndromes, and identify
the major risk factors for fatal outcomes. We hope that these
results will not only assist in the care of children with
malaria, but may also prove valuable in the planning and
assessment of future research.
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